: Shareholders of GWPH American Depositary Shares (ADS) received $200 in cash and $20 in Jazz ordinary shares for each ADS held.
: Beyond Epidiolex, Jazz acquired GW's pipeline of cannabinoid-based drugs for conditions like MS-related spasticity, autism, and schizophrenia.
: Jazz combined its existing focus on sleep disorders and oncology with GW's cannabinoid platform. is gwph a good buy
: The deal was expected to deliver double-digit revenue growth and be accretive to earnings shortly after closing.
If you are interested in the assets formerly owned by GW Pharmaceuticals, you must now look at . To determine if JAZZ is a "good buy," consider the following factors derived from the merger: : Shareholders of GWPH American Depositary Shares (ADS)
: The acquisition was driven largely by GW's blockbuster cannabis-derived drug, Epidiolex , which treats rare forms of childhood epilepsy. How to Invest Now
For current valuation and performance, you should review the latest financial data for on platforms like Yahoo Finance or Seeking Alpha . : The deal was expected to deliver double-digit
: Following the completion of the merger, GWPH was delisted from the Nasdaq.